Cargando…

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Recent studies have identified the key role of crosstalk between dysregulated epithelial cells, mesenchymal, immune, and endothelial cells in IPF. In addition, genetic mutations and environmental factors (e.g., smoking) have a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Hongbo, Wu, Xuyi, Li, Yi, Xia, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349351/ https://www.ncbi.nlm.nih.gov/pubmed/35935869 http://dx.doi.org/10.3389/fphar.2022.963054

Ejemplares similares

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
por: Estornut, Cristina, et al.
Publicado: (2022)

Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
por: Zhang, Tingwei, et al.
Publicado: (2022)

Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis
por: Wang, Fa-Da, et al.
Publicado: (2022)

Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary Fibrosis
por: Fukumoto, Jutaro, et al.
Publicado: (2022)

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
por: Guo, Hehua, et al.
Publicado: (2023)

Feasibility and Mechanism Analysis of Shenfu Injection in the Treatment of Idiopathic Pulmonary Fibrosis
por: Liu, Peipei, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
por: Mei, Qianru, et al.
Publicado: (2022)

Exploring the Mechanism Whereby Sinensetin Delays the Progression of Pulmonary Fibrosis Based on Network Pharmacology and Pulmonary Fibrosis Models
por: Xu, Yong, et al.
Publicado: (2021)

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier
por: Camelo, Ana, et al.
Publicado: (2014)

Small airway dysfunction in idiopathic pulmonary fibrosis
por: Yin, Chengsheng, et al.
Publicado: (2022)

MicroRNAs as potential targets for progressive pulmonary fibrosis
por: Rajasekaran, Subbiah, et al.
Publicado: (2015)

Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis
por: Huang, Guirui, et al.
Publicado: (2022)

Editorial: Molecular Mechanisms and New Therapeutic Targets in Epithelial to Mesenchymal Transition (EMT) and Fibrosis
por: Battistelli, Cecilia, et al.
Publicado: (2020)

Corrigendum: Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis
por: Huang, Guirui, et al.
Publicado: (2022)

Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
por: Habiel, David M., et al.
Publicado: (2014)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer
por: Liu, Xuan, et al.
Publicado: (2022)

Study on the Mechanism of Astragalus Polysaccharide in Treating Pulmonary Fibrosis Based on “Drug-Target-Pathway” Network
por: Bing, Pingping, et al.
Publicado: (2022)

Research Progress on PARP14 as a Drug Target
por: Qin, Wei, et al.
Publicado: (2019)

Laryngopharyngeal pH Monitoring in Patients With Idiopathic Pulmonary Fibrosis
por: Su, Yiliang, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
por: Ballester, Beatriz, et al.
Publicado: (2019)

Editorial: Molecular mechanisms and new therapeutic targets in epithelial to mesenchymal transition (EMT) and fibrosis, volume II
por: Battistelli, Cecilia, et al.
Publicado: (2022)

Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis
por: Wang, Rui, et al.
Publicado: (2022)

The identification of metabolism-related subtypes and potential treatments for idiopathic pulmonary fibrosis
por: Yang, Changqing, et al.
Publicado: (2023)

Integrated analysis of the molecular mechanisms in idiopathic pulmonary fibrosis
por: Zhu, Ke, et al.
Publicado: (2021)

Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis
por: Han, Meishan, et al.
Publicado: (2022)

Drugs and Targets in Fibrosis
por: Li, Xiaoyi, et al.
Publicado: (2017)

Molecular mechanism and research progress on pharmacology of ferulic acid in liver diseases
por: Shi, Yingying, et al.
Publicado: (2023)

Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition
por: Pi, Peng, et al.
Publicado: (2023)

Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis
por: Zhang, Yihang, et al.
Publicado: (2023)

Progress of potential drugs targeted in lipid metabolism research
por: Liang, Kai, et al.
Publicado: (2022)

Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution
por: Samarelli, Anna Valeria, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Progress of research on molecular targeted therapies for colorectal cancer
por: Huang, Shilin, et al.
Publicado: (2023)

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2022)

Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2020)

Integrins and cadherins as therapeutic targets in fibrosis
por: Agarwal, Sandeep K.
Publicado: (2014)

Targeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis
por: Lee, Suh-Young, et al.
Publicado: (2022)

Investigation of the Pharmacological Effect and Mechanism of Jinbei Oral Liquid in the Treatment of Idiopathic Pulmonary Fibrosis Using Network Pharmacology and Experimental Validation
por: Zhang, Aijun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8stf1ibnunj3vlt3299nfkfcbt